Article
Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD.
Journal of neurology, neurosurgery, and psychiatry - 13 Mar 2025
Benatar Michael, Heiman-Patterson Terry D, Cooper-Knock Johnathan, Brickman Daniel, Casaletto Kaitlin B, Goutman Stephen A, Vinceti Marco, Dratch Laynie, Arias Jalayne J, Swidler Jean, Turner Martin R, Shefner Jeremy, Westeneng Henk-Jan, van den Berg Leonard H, Al-Chalabi Ammar
Abstract excerpt
There is a growing understanding of the presymptomatic stages of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and nascent efforts aiming to prevent these devastating neurodegenerative diseases have emerged. This progress is attributable, in no small part, to the altruism of people living with pathogenic variants at elevated genetic risk for ALS/FTD via their willingness to participate in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.